Intellia Therapeutics (NASDAQ:NTLA) Issues Quarterly Earnings Results

Intellia Therapeutics (NASDAQ:NTLA) issued its quarterly earnings results on Thursday. The company reported ($0.80) earnings per share for the quarter, hitting the consensus estimate of ($0.80), FiscalAI reports. Intellia Therapeutics had a negative return on equity of 58.80% and a negative net margin of 672.16%.The business had revenue of $7.66 million during the quarter, compared to the consensus estimate of $12.98 million. During the same quarter last year, the company earned ($0.98) earnings per share. The company’s quarterly revenue was down 46.4% on a year-over-year basis.

Here are the key takeaways from Intellia Therapeutics’ conference call:

• Lonvo-z’s phase III HALO trial succeeded, showing an 87% reduction in mean monthly HAE attacks versus placebo, with 62% of patients attack-free and therapy-free during the six-month evaluation period. Intellia expects FDA acceptance of the rolling BLA by year-end and is preparing for a potential U.S. launch in the first half of 2027.
• Nex-z phase III enrollment and dosing resumed in both ATTR trials during the second quarter after clinical holds were resolved, with screening rates increasing globally. Intellia reported that MAGNITUDE has enrolled more than 650 patients and that blinded event rates remain within its internal projections.
• Intellia identified the HLA-C*05:01 allele as associated with a significantly higher rate of severe transaminase elevations following nex-z treatment. The allele is present in roughly 12% of patients, although most carriers did not experience severe elevations; updated protocols now require HLA typing and enhanced risk disclosure.
• The company ended June with $628.4 million in cash, equivalents, and marketable securities after raising approximately $195 million in net proceeds through an April equity financing. Management believes this provides a cash runway into at least 2028, excluding potential lonvo-z product revenue.
• Second-quarter collaboration revenue declined to $7.7 million from $14.2 million year over year, while net loss widened to $106.6 million from $101.3 million. R&D expenses fell, but G&A increased due to commercial infrastructure build-out, legal costs, and higher stock-based compensation.

Intellia Therapeutics Stock Performance

Shares of NASDAQ NTLA traded up $0.70 during midday trading on Friday, reaching $11.94. 4,923,615 shares of the stock were exchanged, compared to its average volume of 4,163,880. The stock has a market capitalization of $1.67 billion, a P/E ratio of -3.55 and a beta of 1.81. The company has a 50 day simple moving average of $13.65 and a 200 day simple moving average of $13.48. Intellia Therapeutics has a twelve month low of $7.95 and a twelve month high of $28.25.

Analyst Upgrades and Downgrades

NTLA has been the subject of several analyst reports. Leerink Partners set a $35.00 target price on shares of Intellia Therapeutics in a research note on Monday, April 27th. Citigroup restated a “market outperform” rating on shares of Intellia Therapeutics in a research report on Monday, June 15th. Morgan Stanley lifted their price objective on shares of Intellia Therapeutics from $11.00 to $15.00 and gave the company an “equal weight” rating in a report on Monday, April 27th. The Goldman Sachs Group upped their price objective on shares of Intellia Therapeutics from $8.00 to $9.00 and gave the stock a “sell” rating in a research report on Tuesday, April 28th. Finally, Wedbush raised their target price on Intellia Therapeutics from $12.00 to $17.00 and gave the company a “neutral” rating in a research report on Friday, July 10th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, eight have given a Hold rating and four have issued a Sell rating to the stock. According to MarketBeat.com, Intellia Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $20.85.

Insiders Place Their Bets

In other news, CAO Michael P. Dube sold 2,641 shares of the firm’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $16.78, for a total transaction of $44,315.98. Following the completion of the transaction, the chief accounting officer directly owned 66,886 shares in the company, valued at $1,122,347.08. This trade represents a 3.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Edward J. Dulac III sold 4,677 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $18.00, for a total value of $84,186.00. Following the transaction, the executive vice president owned 156,286 shares of the company’s stock, valued at $2,813,148. This trade represents a 2.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 3.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Benjamin Edwards Inc. boosted its stake in Intellia Therapeutics by 1.8% in the 2nd quarter. Benjamin Edwards Inc. now owns 63,034 shares of the company’s stock valued at $591,000 after buying an additional 1,126 shares in the last quarter. Ameriprise Financial Inc. increased its holdings in Intellia Therapeutics by 13.9% during the 2nd quarter. Ameriprise Financial Inc. now owns 11,803 shares of the company’s stock valued at $111,000 after purchasing an additional 1,443 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in Intellia Therapeutics in the third quarter worth $30,000. Advisory Services Network LLC bought a new stake in shares of Intellia Therapeutics during the third quarter worth $33,000. Finally, Northwestern Mutual Wealth Management Co. increased its stake in shares of Intellia Therapeutics by 38.6% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 7,080 shares of the company’s stock valued at $122,000 after buying an additional 1,970 shares in the last quarter. 88.77% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Intellia Therapeutics

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: Evercore ISI upgraded Intellia Therapeutics, citing a favorable “nex-z hypothesis.” The upgrade suggests the firm sees greater potential in Intellia’s gene-editing pipeline, providing the clearest positive catalyst in the recent news flow. Intellia upgraded at Evercore ISI on nex-z hypothesis
• Positive Sentiment: Brookline Capital Markets raised its fourth-quarter 2026 EPS forecast to a loss of $0.41 from $0.47, while projecting a path to profitability beginning in 2027. That outlook supports the longer-term investment case, although the firm made broader reductions to its estimates. Brookline Capital Markets estimates
• Neutral Sentiment: Bank of America Securities maintained a Hold rating, indicating the firm sees neither a sufficiently strong near-term catalyst nor enough downside to change its stance. Bank of America Securities remains a Hold on Intellia Therapeutics
• Negative Sentiment: Intellia’s second-quarter loss was in line with expectations, but revenue fell about 46% year over year to $7.66 million, missing estimates of roughly $12.98 million. The decline was attributed to lower revenue from the Regeneron collaboration, highlighting the company’s reliance on partnership income while it continues to spend heavily on research and development. NTLA Q2 earnings in line, top line misses on lower Regeneron revenues
• Negative Sentiment: Brookline lowered its estimates for the second and third quarters of 2026 and reduced its full-year 2026 forecast to a $2.84 per-share loss. More significantly, projected EPS was cut for 2027 through 2030, including a reduction in 2030 estimates from $68.52 to $25.07, signaling lower expectations for the eventual commercial opportunity.
• Negative Sentiment: WallStreetZen downgraded NTLA to Strong Sell, adding to the bearish analyst commentary and reinforcing concerns about continued losses, execution risk and valuation. Intellia lowered to Strong Sell rating

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.